Nested Variant of Urothelial Carcinoma: A Clinicopathologic and Immunohistochemical Study of 12 Cases

Modern Pathology

Volumn 16, Issue 12, 2003, Pages 1289-1298

  Lin, Oscar ^a   Cardillo, Marina ^b   Dalbagni, Guido ^a   Linkov, Irina ^a   Hutchinson, Brian ^a   Reuter, Victor E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b JACOBI MEDICAL CENTER   (United States)

Author keywords

Immunohistochemistry; Nested; Urothelial carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER INVASION; CARCINOMA; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LAMINA PROPRIA; MALE; METASTASIS; PRIORITY JOURNAL; SUPPRESSOR GENE; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 0347623267     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000094091.04541.FC     Document Type: Article

References (33)

1. Talbert ML, Young RH. Carcinomas of the urinary bladder with deceptively benign-appearing foci. A report of three cases. Am J Surg Pathol 1989;13:374-81.
2. Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998;90:1072-9.
3. Drew PA, Furman J, Civantos F, Murphy WM. The nested variant of transitional cell carcinoma: an aggressive neoplasm with innocuous histology. Mod Pathol 1996;9:989-94.
4. Young RH, Oliva E. Transitional cell carcinomas of the urinary bladder that may be underdiagnosed. A report of four invasive cases exemplifying the homology between neoplastic and non-neoplastic transitional cell lesions. Am J Surg Pathol 1996;20:1448-54.
5. Murphy WM, Deana DG. The nested variant of transitional cell carcinoma: a neoplasm resembling proliferation of Brunn's nests. Mod Pathol 1992;5:240-3.
6. Tatsura H, Ogawa K, Sakata T, Okamura T. A nested variant of transitional cell carcinoma of the urinary bladder: a case report. Jpn J Clin Oncol 2001;31:287-9.
7. Ozdemir BH, Ozdemir G, Sertcelik A. The nested variant of the transitional cell bladder carcinoma: a case report and review of the literature. Int Urol Nephrol 2000;32:257-8.
8. Paik SS, Park MH. The nested variant of transitional cell carcinoma of the urinary bladder. Br J Urol 1996;78:793-4.
9. Kamai T, Takagi K, Asami H, Ito Y, Oshima H, Yoshida KI. Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer 2001;84:1242-51.
10. Korkolopoulou P, Christodoulou P, Konstantinidou AE, Thomas-Tsagli E, Kapralos P, Davaris P. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. Hum Pathol 2000;31:751-60.
11. Qureshi KN, Griffiths TR, Robinson MC, Marsh C, Roberts JT, Lunec J, et al. Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy. Int J Radiat Oncol Biol Phys 2001;51:1234-40.
12. Pfister C, Larue H, Moore L, Lacombe L, Veilleux C, Tetu B, et al. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes. Int J Cancer 2000;89:100-4.
13. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995;147:545-60.
14. Baithun SI, Naase M, Blanes A, Diaz-Cano SJ. Molecular and kinetic features of transitional cell carcinomas of the bladder: biological and clinical implications. Virchows Arch 2001;438:289-97.
15. Wolf HK, Stober C, Hohenfellner R, Leissner J. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas. Tumour Biol 2001;22:328-36.
16. Ong F, Moonen LM, Gallee MP, ten Bosch C, Zerp SF, Hart AA, et al. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother Oncol 2001;61:169-75.
17. Pfister C, Moore L, Allard P, Larue H, Lacombe L, Tetu B, et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 1999;5:4079-84.
18. Sauter G, Haley J, Chew K, Kerschmann R, Moore D, Carroll P, et al. Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int J Cancer 1994;57:508-14.
19. Eble JN, Young RH. Carcinoma of the urinary bladder: a review of its diverse morphology. Semin Diagn Pathol 1997;14:98-108.
20. Stern JB. Unusual benign bladder tumor of Brunn nest origin. Urology 1979;14:288-9.
21. Cardillo M, Reuter VE, Lin O. Cytologic features of the nested variant of urothelial carcinoma: a study of seven cases. Cancer 2003;99:23-7.
22. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994;369:574-8.
23. Clasen S, Schulz WA, Gerharz CD, Grimm MO, Christoph F, Schmitz-Drager BJ. Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma. Br J Cancer 1998;77:515-21.
24. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85:53-9.
25. Popov Z, Hoznek A, Colombel M, Bastuji-Garin S, Lefrere-Belda MA, Bellot J, et al. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 1997;80:1472-81.
26. Asakura T, Takano Y, Iki M, Suwa Y, Noguchi S, Kubota Y, et al. Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer. J Urol 1997;158:385-8.
27. Limas C. Proliferative state of the urothelium with benign and atypical changes. Correlation with transferrin and epidermal growth factor receptors and blood group antigens. J Pathol 1993;171:39-47.
28. Isimbaldi G, Di Nuovo F, Sironi M, Catania G, Bonacina R, Privitera O, et al. [Nephrogenic adenoma of the bladder. Morphological and immunophenotypic study with particular attention to differential diagnosis]. Pathologica 1999;91:192-7.
29. Pycha A, Mian C, Reiter WJ, Brossner C, Haitel A, Wiener H, et al. Nephrogenic adenoma in renal transplant recipients: a truly benign lesion? Urology 1998;52:756-61.
30. Valero Puerta JA, Redondo Martinez E, Jiemenez Gonzalez C, Gomez Medina ML, Martinez de la Riva SI. [Inverted transitional-cell papilloma: the expression of the Ki-67 nuclear antigen as a prognostic factor]. Arch Esp Urol 1995;48:887-92.
31. Messing EM. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 1990;50:2530-7.
32. Voorter C, Joos S, Bringuier PP, Vallinga M, Poddighe P, Schalken J, et al. Detection of chromosomal imbalances in transitional cell carcinoma of the bladder by comparative genomic hybridization. Am J Pathol 1995;146:1341-54.
33. Diaz-Cano SJ, Blanes A, Rubio J, Matilla A, Wolfe HJ. Molecular evolution and intratumor heterogeneity by topographic compartments in muscle-invasive transitional cell carcinoma of the urinary bladder. Lab Invest 2000;80:279-89.